Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: 1‐year outcomes of the multicentre, randomized ECMO‐CS trial.

Bibliographic Details
Title: Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: 1‐year outcomes of the multicentre, randomized ECMO‐CS trial.
Authors: Ostadal, Petr, Rokyta, Richard, Karasek, Jiri, Kruger, Andreas, Vondrakova, Dagmar, Janotka, Marek, Naar, Jan, Smalcova, Jana, Hubatova, Marketa, Hromadka, Milan, Volovar, Stefan, Seyfrydova, Miroslava, Linhart, Ales, Belohlavek, Jan
Source: European Journal of Heart Failure; Jan2025, Vol. 27 Issue 1, p30-36, 7p
Subject Terms: HEART assist devices, EXTRACORPOREAL membrane oxygenation, CARDIOGENIC shock, INTENSIVE care units, CARDIAC arrest, ARTIFICIAL respiration
Abstract: Aims: Among patients with cardiogenic shock, immediate initiation of extracorporeal membrane oxygenation (ECMO) did not demonstrate any benefit at 30 days. The present study evaluated 1‐year clinical outcomes of the Extracorporeal Membrane Oxygenation in the therapy of Cardiogenic Shock (ECMO‐CS) trial. Methods and results: The ECMO‐CS trial randomized 117 patients with severe or rapidly progressing cardiogenic shock to immediate initiation of ECMO or early conservative strategy. The primary endpoint for this analysis was 1‐year all‐cause mortality. Secondary endpoints included a composite of death, resuscitated cardiac arrest or implantation of another mechanical circulatory support device, duration of mechanical ventilation, and the length of intensive care unit (ICU) and hospital stays. In addition, an unplanned post‐hoc subgroup analysis was performed. At 1 year, all‐cause death occurred in 40 of 58 (69.0%) patients in the ECMO arm and in 40 of 59 (67.8%) in the early conservative arm (hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.66–1.58; p = 0.93). The composite endpoint occurred in 43 (74.1%) patients in the ECMO group and in 47 (79.7%) patients in the early conservative group (HR 0.83, 95% CI 0.55–1.25; p = 0.29). The durations of mechanical ventilation, ICU stay and hospital stay were comparable between groups. Significant interaction with treatment strategy and 1‐year mortality was observed in subgroups according to baseline mean arterial pressure (MAP) indicating lower mortality in the subgroup with low baseline MAP (<63 mmHg: HR 0.58, 95% CI 0.29–1.16; pinteraction = 0.017). Conclusions: Among patients with severe or rapidly progressing cardiogenic shock, immediate initiation of ECMO did not improve clinical outcomes at 1 year compared to the early conservative strategy. However, immediate ECMO initiation might be beneficial in patients with advanced haemodynamic compromise. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Heart Failure is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:13889842
DOI:10.1002/ejhf.3398
Published in:European Journal of Heart Failure
Language:English